Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04493255
Other study ID # E7090-E044-002
Secondary ID 2019-004957-10
Status Completed
Phase Phase 1
First received
Last updated
Start date September 9, 2020
Est. completion date October 21, 2020

Study information

Verified date July 2020
Source Eisai Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective of this study is to determine the pharmacokinetics (PK) and excretion of E7090 and its metabolites in healthy male participants. Also, to assess the safety and tolerability of a single dose of E7090 in healthy male participants.


Recruitment information / eligibility

Status Completed
Enrollment 8
Est. completion date October 21, 2020
Est. primary completion date October 21, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 35 Years to 55 Years
Eligibility Inclusion Criteria: 1. Non-smoking, healthy males, age greater than or equal to (>=) 35 years and less than or equal to (<=) 55 years old at the time of informed consent 2. Body Mass Index (BMI) of >=18 to <=32 kilogram per square meter (kg/m^2) at Screening 3. Provide written informed consent 4. Willing and able to comply with all aspects of the protocol 5. History of a minimum of 1 bowel movement per day Exclusion Criteria: 1. Participant has participated in any clinical research study involving a radiolabeled investigational product within the 12 months prior to Day -1 (Baseline) 2. Participant has previously completed or withdrawn from this study or any other study investigating E7090 or previously received E7090 3. Participant has had exposure to significant diagnostic or therapeutic radiation (example: serial x-ray, computed tomography scan, barium meal) or has current employment in a job requiring radiation exposure monitoring within 12 months prior to Day -1 4. Participant has the following ocular disorders: 1. Any previous history or current evidence of corneal disorder 2. Any previous history or current evidence of active macular disorder (example: age-related macular degeneration, central serous chorioretinal disease) 5. Participants has a known history of clinically significant drug allergy at Screening or Baseline (Day -1) 6. Participants has a known history of food allergies or significant seasonal or perennial allergy 7. Participants is known to be human immunodeficiency virus positive at Screening 8. Participants has active viral hepatitis (B or C) as demonstrated by positive serology at Screening 9. Participant has a poor peripheral venous access, in the opinion of the investigator (or designee) 10. Participant received blood products within 2 months prior to Day -1, or donation of blood within 3 months prior to Screening, donation of plasma within 2 weeks prior to Screening, or donation of platelets from 6 weeks prior to Screening

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
[14C]E7090
[14C]E7090, oral capsule.

Locations

Country Name City State
United Kingdom Covance Clinical Research Unit Leeds

Sponsors (1)

Lead Sponsor Collaborator
Eisai Limited

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary feu: Percentage of Administered Radioactive Dose of [14C]E7090 Excreted in Urine Up to Day 57
Primary Cumulative feu: Cumulative Percentage of Administered Radioactive Dose of [14C]E7090 Excreted in Urine From 0 to tlast Hours Up to Day 57
Primary fef: Percentage of Administered Radioactive Dose of [14C]E7090 Excreted in Feces Up to Day 57
Primary Cumulative fef: Cumulative Percentage of Administered Radioactive Dose of [14C]E7090 Excreted in Feces From 0 to tlast Hours Up to Day 57
Primary feu+ef: Percentage of Administered Radioactive Dose excreted of [14C]E7090 in Combined Excreta (Urine and Feces) Up to Day 57
Primary Cumulative feu+ef: Cumulative Percentage of Administered Radioactive Dose excreted of [14C]E7090 in Combined Excreta (Urine and Feces) From 0 to tlast Hours Up to Day 57
Primary Cmax: Maximum Observed Plasma Concentration for [14C]E7090, E7090 and its Metabolites Day 1: 0-672 hours post-dose
Primary Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for [14C]E7090, E7090 and its Metabolites Day 1: 0-672 hours post-dose
Primary AUC(0-24h): Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours Postdose for [14C]E7090, E7090 and its Metabolites Day 1: 0-24 hours post-dose
Primary AUC(0-t): Area Under the Concentration- time Curve From Time 0 to Time of Last Quantifiable Concentration for [14C]E7090, E7090 and its Metabolites Day 1: 0-672 hours post-dose
Primary AUCinf: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for [14C]E7090, E7090 and its Metabolites Day 1: 0-672 hours post-dose
Primary T1/2: Terminal Elimination Phase Half-life for [14C]E7090, E7090 and its Metabolites Day 1: 0-672 hours post-dose
Primary CL/F: Apparent Total Body Clearance for E7090 Day 1: 0-672 hours post-dose
Primary Vd/F: Apparent Volume of Distribution for E7090 Day 1: 0-672 hours post-dose
Primary MPR AUC(0-inf): Metabolite to Parent Ratio For AUC(0-inf) of Metabolite to E7090, Corrected for Molecular Weights Day 1: 0-672 hours post-dose
Secondary Metabolic profile of E7090: Concentration of Metabolite of E7090 in Plasma, Urine, and Feces Blood, urine and feces samples will be collected and analyzed to estimate the concentration of metabolite of E7090 by Liquid Chromatography/ multiple-stage Mass Spectroscopy method. Up to Day 57
Secondary Number of Participants With Treatment-emergent Adverse Events (TEAEs) Baseline up to Day 57
Secondary Number of Participants With Clinically Significant Change From Baseline in Laboratory Parameters Values Baseline up to Day 29
Secondary Number of Participants With Clinically Significant Change From Baseline in Vital Signs Values Baseline up to Day 29
Secondary Number of Participants With Clinically Significant Change From Baseline in 12 Lead Electrocardiogram (ECG) Findings Baseline up to Day 29
Secondary Number of Participants With Any Suicidality Assessed Using Columbia-Suicide Severity Rating Scale (C-SSRS) The C-SSRS is an interview-based rating scale to systematically assess any suicidality, any suicidal behavior, any suicidal ideation. Any suicidality: emergence of any suicidal ideation or suicidal behavior. Any suicidal behavior: when response is "yes" for any these questions- actual attempt to suicide, engaged in non-suicidal self-injurious behavior, interrupted attempt, aborted attempt, preparatory acts. Any suicidal ideation: when response is "yes" for any of these questions- wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent to suicide. Number of participants with any suicidality will be reported for this outcome measure. Baseline up to Day 29
Secondary Number of Participants With Clinically Significant Change From Baseline in Ophthalmic Examinations Ophthalmic examinations includes visual acuity, funduscopy, optical coherence tomography, and slit-lamp examination. Baseline up to Day 29
Secondary Number of Participants With Clinically Significant Change From Baseline in Physical Examinations Baseline up to Day 29
See also
  Status Clinical Trial Phase
Completed NCT05001152 - Taste Assessment of Ozanimod Phase 1
Completed NCT05029518 - 3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability Phase 1
Completed NCT03457649 - IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers Phase 1
Completed NCT00995891 - Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
Completed NCT05043766 - Evaluation of Oral PF614 Relative to OxyContin Phase 1
Completed NCT05050318 - Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively Phase 4
Completed NCT04466748 - A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects Phase 1
Completed NCT00746733 - Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC Phase 1
Recruiting NCT05929651 - Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy Phase 4
Completed NCT05954039 - Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect N/A
Completed NCT05045716 - A Study of Subcutaneous Lecanemab in Healthy Participants Phase 1
Active, not recruiting NCT02747927 - Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Phase 3
Completed NCT05533801 - A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants Phase 1
Not yet recruiting NCT03931369 - Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) Phase 2
Completed NCT03279146 - A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects Phase 1
Completed NCT06027437 - A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants Phase 1
Recruiting NCT05619874 - Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity N/A
Completed NCT05553418 - Investigational On-body Injector Clinical Study N/A
Completed NCT04092712 - Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers Phase 1
Not yet recruiting NCT06236009 - A First-In-Human Study of TAK-004 in Healthy Adults Phase 1